HTS Chapter 30 covers pharmaceutical products – finished medicaments (HS 3003-04), bandages and pharmaceutical kits (3005-06). APIs typically classify in HS 2941 (Chapter 29). Section 232 pharma effective July 31 covers branded patented drugs in Chapter 30; generics and biosimilars excluded.
This guide covers HTS Chapter 30 Pharmaceutical Products. HTS classification is the legal foundation of import duty calculation.
For SMB importers, the practical implementation depends on volume, sector, and operational structure.
Chapter 30 structure
Headings 3001-3006. Glands and organ extracts (3001), human/animal blood (3002), medicaments (3003-3004), bandages (3005), pharmaceutical kits (3006).
HS 3003 vs 3004
3003: finished medicaments not in measured doses. 3004: finished medicaments in measured doses (tablets, capsules). Most finished pharma is HS 3004.
APIs in HS 2941
Active Pharmaceutical Ingredients typically classify in HS 2941 (Chapter 29) rather than Chapter 30.
Section 232 pharma scope
Section 232 effective July 31 covers branded patented drugs. Generics and biosimilars excluded. USMCA-qualifying pharma exempt from Section 122.
Frequently asked questions
When does this apply?
For SMB importers with active duty exposure or those evaluating mitigation options.
What documentation is required?
Standard CBP forms plus topic-specific supporting records. We review documentation as part of typical engagements.
What is the timeline?
Simple cases 2-4 weeks; complex setups 8-16 weeks.
What does this cost?
Project work: $5,000-$25,000 depending on complexity. Ongoing retainer for active operations.
How do I begin?
Book a 15-minute scoping call. We confirm fit and scope before any engagement.
Get started
Get a paid classification opinion or binding ruling support. Fixed-fee per HTS code.